SEC 13F Intelligence

Payden & Rygel / DGX

Payden & Rygel’s Quest Diagnostics Inc Position

Does Payden & Rygel own Quest Diagnostics Inc (DGX)? Yes76.6K shares worth $15M (+1.16% of its 13F portfolio) as of Q1 2026, down from 93.4K shares the prior filed quarter.

Position Value
$15M
Q1 2026
Shares
76.6K
% of Portfolio
+1.16%
Quarters Held
4
currently held

Position History DGX

Reported value by quarter
Q2 ’25: $17MQ2 ’25Q3 ’25: $18MQ3 ’25Q4 ’25: $16MQ4 ’25Q1 ’26: $15MQ1 ’26filingsflow.com
QuarterSharesValue% of Portfolio
Q1 202676.6K$15M+1.16%
Q4 202593.4K$16M+1.12%
Q3 202594.2K$18M+1.49%
Q2 202593.6K$17M+1.39%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Payden & Rygel’s full portfolio or all institutional holders of DGX.